From the Popular Press: What Your Patients are Reading:

According to a new report published in the Journal of the American Academy of Dermatology, the use of thiazolidinediones type diabetes drugs may reduce the risk of developing psoriasis. Avandia^® and Actos^® are two popular thiazolidinediones used to treat diabetes. The drugs have anti-inflammatory effects, leading researchers to hypothesize that they might be beneficial in treating diseases such as psoriasis, which involves widespread inflammation. Study results show that regular use of thiazolidinediones reduced the risk of psoriasis by 67%. Metformin, an older diabetes drug, also cut the risk of psoriasis but not as drastically. These numbers are based on a small number of patients, however. Further research is needed to confirm the results of the study. In the future, thiazolidinediones may be used as a new treatment option in the management of psoriasis. Patients diagnosed with both diabetes and psoriasis should talk with their doctor about treatment with thiazolidinediones.

Read the full text of the article on reutershealth.com